{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
diltiazem
to a specific field?
There is one exact (name or code) match for diltiazem
Status:
US Approved Rx
(2023)
Source:
ANDA216327
(2023)
Source URL:
First approved in 1982
Source:
NDA018602
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Diltiazem is a nondihydropyridines calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia. Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance.
Status:
US Approved Rx
(2023)
Source:
ANDA216327
(2023)
Source URL:
First approved in 1982
Source:
NDA018602
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Diltiazem is a nondihydropyridines calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia. Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance.
Status:
US Approved Rx
(2008)
Source:
NDA022156
(2008)
Source URL:
First approved in 2008
Source:
NDA022156
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Clevidipine is a dihydropyridine calcium channel blocker. Clevidipine is marketed under the trade name Cleviprex, indicated for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable. Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. Clevidipine does not reduce cardiac filling pressure (pre-load), confirming lack of effects on the venous capacitance vessels.
Status:
US Approved Rx
(1987)
Source:
ANDA070738
(1987)
Source URL:
First approved in 1978
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Verapamil is a FDA approved drug used to treat high blood pressure and to control chest pain. Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias. Verapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.
![Structure of Des[5-(2-dimethylamino)ethyl] Diltiazem 5-Ethenyl](/img/4304757d-ba20-4b22-a236-a1569d0a0ca2.svg?size=200&context=jrjudenkob)
